Welcome to our dedicated page for Medirom Healthcare Technologies SEC filings (Ticker: MRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. MEDIROM files annual reports on Form 20-F and furnishes current and interim information on Form 6-K under the Securities Exchange Act of 1934. These documents offer detailed insight into the company’s relaxation salon operations, digital preventative healthcare activities, luxury beauty segment, and health-tech initiatives.
Form 6-K reports for MEDIROM frequently include press releases and explanatory notes about key corporate events. Recent examples cover the issuance and closing of Third Unsecured Convertible-Type Corporate Bonds with Share Options, including terms such as interest accrual, maturity dates, conversion options into common shares, and redemption provisions. Other 6-K filings furnish interim financial information, major Key Performance Indicators (KPIs), and updates on equity financing rounds at subsidiary MEDIROM MOTHER Labs Inc.
Through these filings, investors can review how MEDIROM structures its capital and financing, including unsecured short-term bank loans, convertible debt, and bond issuances conducted outside the United States under Regulation S. The filings also describe how proceeds are intended to be used for general corporate or financing purposes, subject to the company’s decisions over time.
Segment disclosures embedded in MEDIROM’s interim reports identify the Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty segments, along with revenue categories such as franchisor-owned outlets, franchise revenue, royalty revenue, sublease revenue, staffing service revenue, and other franchise-related income. These details help readers understand how the MEDIROM Group organizes its operations and reports performance across its salon network and health-tech businesses.
On Stock Titan, each newly furnished MEDIROM Form 6-K or other SEC document is made available with AI-powered summaries that highlight the most important points, such as financing terms, segment information, and material corporate announcements. Real-time updates from EDGAR ensure that filings related to topics like convertible bonds, treasury strategies involving digital assets, and subsidiary equity financings are accessible soon after publication. Users can quickly scan AI-generated explanations of lengthy reports, then open the full text for deeper review when needed.
For investors tracking MRM, this filings page is a central resource for reviewing MEDIROM’s official disclosures on capital structure, segment reporting, and material events as presented in its SEC submissions.
Healthcare Technologies Inc. has called its 26th Ordinary General Meeting of Shareholders for May 29, 2026 to approve Japanese GAAP non‑consolidated financial statements for fiscal 2025 and elect five directors, including two outside directors. The board unanimously recommends voting “FOR” all proposals and stresses the importance of proxy voting for holders unable to attend in Tokyo.
Under Japanese GAAP, fiscal 2025 revenue was JPY 604,533 thousand and net income was JPY 56,058 thousand, with a capital adequacy ratio of 32.11%. The company continued reorganizing its relaxation salon operations, expanded its healthtech and rehabilitation businesses, and raised JPY 400 million via 3rd series unsecured convertible‑type bonds. It also issued a 4th series of convertible‑type bonds with a balance of JPY 275 million and maintained total assets of JPY 4,153,929 thousand and net assets per common share of JPY 168.32 at year‑end.
Healthcare Technologies Inc. entered a new Memorandum of Understanding with Kufu Company Holdings Inc. on March 31, 2026 to adjust an existing financing arrangement. The parties agreed to extend the maturity date of their previously disclosed Deemed Loan Agreement from March 31, 2026 to April 30, 2026, giving the Company an extra month before repaying principal under that loan. All interest that had accrued through March 31, 2026 under the Loan Agreement became due and payable when this new memorandum was executed, while all other loan terms remain unchanged. The company is also incorporating this report, including the exhibit containing the memorandum, by reference into its existing registration statements on Form S-8 and Form F-3.
Kufu Company Holdings, Inc. filed an amended ownership report on Medirom Healthcare Technologies Inc., showing beneficial ownership of 833,333 common shares, or 9.44% of the company on an as-converted basis. These shares are issuable upon conversion of unsecured convertible-type corporate bonds.
On December 31, 2025, Kufu purchased Medirom’s Fourth Unsecured Convertible-Type Corporate Bonds with share options for an aggregate JPY 275,000,000, funded with cash on hand. The bonds bear 5.0% annual interest until the June 30, 2026 maturity date, with a possible extension to December 25, 2026, and are convertible at JPY 330 per common share.
The filing explains that part of the new bonds refinanced JPY 275,000,000 of principal from earlier convertible bonds issued in 2022 that matured on December 31, 2025. Kufu states it holds the investment for general investment purposes and may reassess its position based on Medirom’s performance and market conditions.
Medirom Healthcare Technologies Inc. director Ogawa Tomoya filed an initial ownership report showing he directly holds 28,500 Common Shares of the company. This filing is a baseline disclosure of his equity stake and does not reflect any new share purchases or sales.
Medirom Healthcare Technologies Inc. director Nojima Akira has reported initial beneficial ownership of 1,200 Common Shares. These shares are held directly, and the filing does not reflect any recent buy or sell activity, only the director’s current equity position in the company.
Medirom Healthcare Technologies Inc. filed an initial ownership report for Chief Financial Officer and director Fujiwara Fumitoshi. The filing shows direct beneficial ownership of 40,000 Common Shares following the reported position. This Form 3 does not reflect any new purchase or sale transactions, only the existing holdings.
Medirom Healthcare Technologies Inc. director and Chief Executive Officer Eguchi Kouji filed an initial ownership report showing his existing stake in the company. He directly holds 1,877,460 common shares, plus additional indirect holdings, and holds options to purchase 150,000 common shares and 36,500 common shares at stated exercise prices and terms.
Healthcare Technologies Inc. reported that its Master Service Agreement with Tools for Humanity and World Foundation became effective on February 2, 2026. The partnership is tied to deployment of Orbs biometric devices in Japan.
The company currently has Orbs at more than 150 locations, with cumulative authentications exceeding 20,000. Based on current performance, if it expands to about 3,000 locations nationwide in Japan, Healthcare Technologies estimates it could generate approximately USD 39 million (about JPY 6.10 billion) in income before income taxes over the next two years under the agreement, though this projection is forward-looking and subject to risks.
Healthcare Technologies Inc. has refinanced maturing debt with a mix of new convertible bonds and a secured loan to its main lender, Kufu Company Holdings Inc. The company issued fourth unsecured convertible corporate bonds totaling JPY 275,000,000 at 5.0% interest, maturing on June 30, 2026, with an option to extend to December 25, 2026. These bonds can be converted into common shares at JPY 330 per share during a defined exercise period, instead of being repaid in cash. Separately, JPY 200,000,000 of the earlier bonds were refinanced into a loan bearing 10.0% interest and due March 31, 2026, secured by a pledge over all shares of subsidiary MOTHER Labs Inc. The remaining JPY 25,000,000 of the original bonds was repaid in cash.
Healthcare Technologies Inc. reported updated key performance indicators for December 2025. Its salon operation business served 70,499 customers, with record-high sales per customer of JPY 7,926 per visit and a repeat customer ratio of 77.8%, above the Japanese industry average sales per customer of JPY 4,806.
The company will shift from monthly to quarterly KPI disclosures starting with the December 2025 release. It also highlighted a compensated World ID initiative launched with Tools for Humanity and Hakuhodo Inc. and, in its Lav® health tech business, contracts with 102 corporate insurance associations and 12,398 cumulative app users as of December 2025.